Zacks Investment Research cut shares of Balchem (NASDAQ:BCPC) from a buy rating to a hold rating in a research note released on Tuesday morning.
According to Zacks, “Balchem Corporation provides state-of-the-art solutions and the finest quality products for a range of industries worldwide. Balchem Company consists of four business segments: Human Nutrition & Health; Animal Nutrition & Health; Specialty Products; and Industrial Products. The Human Nutrition & Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition & Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market. The Industrial Products segment manufactures and supplies certain derivative products into industrial applications. “
Several other research firms have also recently issued reports on BCPC. BidaskClub cut shares of Balchem from a hold rating to a sell rating in a research report on Friday, March 1st. Seaport Global Securities assumed coverage on shares of Balchem in a research report on Thursday, February 21st. They issued a neutral rating on the stock. Finally, HC Wainwright set a $101.00 target price on shares of Balchem and gave the stock a buy rating in a research report on Tuesday, February 5th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company. Balchem presently has an average rating of Hold and a consensus target price of $105.50.
Balchem (NASDAQ:BCPC) last issued its quarterly earnings results on Thursday, February 28th. The basic materials company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.11. Balchem had a net margin of 12.21% and a return on equity of 14.59%. The business had revenue of $163.50 million during the quarter, compared to the consensus estimate of $161.42 million. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. On average, research analysts predict that Balchem will post 3.02 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. NumerixS Investment Technologies Inc acquired a new stake in shares of Balchem in the fourth quarter worth approximately $39,000. Pearl River Capital LLC acquired a new stake in shares of Balchem in the fourth quarter worth approximately $45,000. Hsbc Holdings PLC acquired a new stake in shares of Balchem in the third quarter worth approximately $212,000. Bank of Montreal Can boosted its position in shares of Balchem by 13.6% in the fourth quarter. Bank of Montreal Can now owns 1,926 shares of the basic materials company’s stock worth $151,000 after acquiring an additional 231 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new position in Balchem during the third quarter valued at approximately $247,000. 86.56% of the stock is currently owned by institutional investors and hedge funds.
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.
Recommended Story: Day Trading – Risk Worth the Reward?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.